Effects of 4‐month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID‐19 infection
European Journal of Clinical Investigation · 2025-07 · 55 (7)
DOI: 10.1111/eci.70058 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 24.04.2025. Verfasst von George Pavlidis und 15 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: COVID-19, Dietary Supplements, Endothelium, Vascular, Glycocalyx. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Coronavirus disease 2019 ( COVID ‐19) has been associated with impaired endothelial and vascular function. We investigated whether intervention with glycocalyx dietary supplement ( GDS ), containing glucosamine sulfate and fucoidan, improves endothelial glycocalyx and vascular function after COVID ‐19 infection.
Methods
Fifty‐seven convalescent patients 14 days after mild‐to‐moderate COVID ‐19 infection managed in an outpatient setting were randomized to receive GDS ( n = 29) or placebo ( n = 28) for 4 consecutive months. We measured at baseline and at 4 months: (a) perfused boundary region ( PBR ) of the sublingual microvessels with a diameter range of 4–25 μm, as a marker of endothelial glycocalyx integrity, (b) pulse wave velocity and augmentation index, (c) coronary flow reserve using Doppler echocardiography, and (d) malondialdehyde and protein carbonyls as oxidative stress markers.
Results
Four months after treatment, patients who received GDS showed a greater reduction in PBR 4–25 μm (−6.8% vs. −1.3%), pulse wave velocity (−13.2% vs. −3%), augmentation index (−28.5% vs. −2.5%), malondialdehyde (−26% vs. −2.9%), protein carbonyls (−31.3% vs. −1%) and a greater increase in coronary flow reserve (12.9% vs. 1.6%) compared to placebo ( p < .05). In the GDS group, the reduction in PBR 4–25 μm was associated with the corresponding decrease in pulse wave velocity ( r = .31, p = .047), malondialdehyde, and protein carbonyls, as well as with the increase in coronary flow reserve ( r = −.59, p = .008) at follow‐up. Post‐treatment, none of the patients under GDS reported post‐ COVID symptoms compared to 21.4% of the patients under placebo.
Conclusion
Four‐month treatment with GDS may improve endothelial glycocalyx and vascular function after COVID ‐19 infection. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT05185934.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- 2nd Propaedeutic Department of Internal Medicine, Research Unit and Diabetes Center, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Laboratory of Pharmacology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
- University Department of Emergency Medicine, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- GlycoCalyx Research Institute, Alpine, Utah, USA.
- 4th Department of Internal Medicine, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Konstantinos Katogiannis, Ignatios Ikonomidis
Zitieren
APA
Pavlidis, G., Kountouri, A., Katogiannis, K., Thymis, J., Nikolaou, P. E., Chania, C., Karalis, J., Kostelli, G., Michalopoulou, E., Katsanaki, E., Parissis, J., Vink, H., Long, R., Tsiodras, S., Lambadiari, V., & Ikonomidis, I. (2025). Effects of 4‐month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID‐19 infection. European Journal of Clinical Investigation, 55(7). https://doi.org/10.1111/eci.70058
Vancouver
Pavlidis G, Kountouri A, Katogiannis K, Thymis J, Nikolaou PE, Chania C, et al. Effects of 4‐month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID‐19 infection. European Journal of Clinical Investigation. 2025;55(7). doi:10.1111/eci.70058
BibTeX
@article{Pavlidis2025,
author = {Pavlidis, George and Kountouri, Aikaterini and Katogiannis, Konstantinos and Thymis, John and Nikolaou, Panagiota Efstathia and Chania, Christina and Karalis, John and Kostelli, Gabriella and Michalopoulou, Eleni and Katsanaki, Eleni and Parissis, John and Vink, Hans and Long, Robert and Tsiodras, Sotirios and Lambadiari, Vaia and Ikonomidis, Ignatios},
title = {Effects of 4‐month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID‐19 infection},
journal = {European Journal of Clinical Investigation},
year = {2025},
volume = {55},
number = {7},
doi = {10.1111/eci.70058}
}
EUVIMED